LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)...
Hence then, the article about hansa biopharma data at the 2025 pns annual meeting demonstrates potential of imlifidase in the treatment of gbs was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS )
Also on site :
- Harrison Ford Is Officially Coming to Walt Disney World as an Animatronic Indy for the Very First Time
- 1973 Classic Rock Song, Named Among the ‘Greatest Opening Song Lines’ of All Time, Was Built on a Word Steve Miller Misheard
- ‘The Pitt’ Showrunner Admits Season One’s Notoriety Amped Up Pressure For Season Two: “We Had to Prove That It Wasn’t Just a Fluke”